Combination therapy of lymphoma
The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 07. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
AMENGUAL JENNIFER EFFIE [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-03-07, Last update posted on www.tib.eu: 2023-06-30, Last updated: 2023-07-08 |
|---|
| Patentnummer: |
US11597933 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016590198 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016590198 | ||
| 003 | DE-627 | ||
| 005 | 20230708143521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016590198 | ||
| 035 | |a (EPA)US11597933 | ||
| 035 | |a (EPA)66665816 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a AMENGUAL JENNIFER EFFIE |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination therapy of lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-03-07, Last update posted on www.tib.eu: 2023-06-30, Last updated: 2023-07-08 | ||
| 520 | |a The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LUE JENNIFER |4 aut | |
| 700 | 0 | |a O'CONNOR OWEN A |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 07. März |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/66665816/publication/US11597933A1?q=US11597933 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 07 |c 03 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 03 | ||